<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712203</url>
  </required_header>
  <id_info>
    <org_study_id>200783</org_study_id>
    <nct_id>NCT02712203</nct_id>
  </id_info>
  <brief_title>MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.</brief_title>
  <official_title>Measles-mumps-rubella and Measles-mumps-rubella-varicella Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy children who received two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated
      measles-mumps-rubella vaccine (MMR) or measles-mumps-rubella-varicella vaccine (MMRV) in
      their second year of life.The purpose of this study is to assess the effect of the age at
      administration of the first dose on the reactogenicity and immunogenicity of the measles
      component of these vaccines.

      In addition, this study will evaluate if the effect of the age at first dose is modified by
      the type of vaccine administered.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2004</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Short term seropositivity rates &amp; anti-measles antibody titers after vaccination with MMR or MMRV</measure>
    <time_frame>At day 42 after administration of a dose of MMR or MMRV vaccine</time_frame>
    <description>Antibody titers are expressed as Geometric Mean Concentrations (GMC) in mIU/mL. The cut-off for seropositivity is anti-measles antibody titer ≥ 150 mIU/mL (performed on seronegative subjects prior to vaccination).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Injection site reaction</measure>
    <time_frame>Days 0-3 after vaccination</time_frame>
    <description>Injection site reaction is defined by the presence of pain, redness and swelling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic symptoms</measure>
    <time_frame>Days 0 - 42 after administration of a dose of MMR or MMRV vaccine</time_frame>
    <description>Will include fever (defined as rectal temperature ≥38°C), general malaise and measles-like rash</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term seropositivity rates and anti-measles antibody titers after vaccination with MMR or MMRV</measure>
    <time_frame>2 and 3 years after vaccination with 2 doses of MMR or MMRV vaccines</time_frame>
    <description>Antibody titers are expressed as Geometric Mean Concentrations (GMC) in mIU/mL The cut-off for seropositivity is anti-measles antibody titer ≥ 150 mIU/mL</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">5808</enrollment>
  <condition>Measles</condition>
  <arm_group>
    <arm_group_label>12 months</arm_group_label>
    <description>MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13 months</arm_group_label>
    <description>MMR vaccine / MMRV vaccine : administration of the first dose at 13 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14 months</arm_group_label>
    <description>MMR vaccine / MMRV vaccine : administration of the first dose at 14 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 months or more</arm_group_label>
    <description>MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age or older</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MMR vaccine / MMRV vaccine</intervention_name>
    <description>Subcutaneous injection, two doses</description>
    <arm_group_label>12 months</arm_group_label>
    <arm_group_label>13 months</arm_group_label>
    <arm_group_label>14 months</arm_group_label>
    <arm_group_label>15 months or more</arm_group_label>
    <other_name>Priorix®</other_name>
    <other_name>Priorix-Tetra®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects aged 11 to 22 months selected to participate in clinical trials to assess the
        safety and immunogenicity of the GSK biological Priorix-Tetra™ in Germany, Austria,
        Finland, Greece, Poland, Czech Republic, Italy, Lithuania, Norway, Romania, Russian
        Federation, Slovakia, Sweden, United States and Puerto Rico.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subject between 11 to 22 months at the time of first
             vaccination.

          -  Written informed consent obtained from the parent/guardian of the subject.

        Exclusion Criteria:

          -  History of previous measles, mumps, rubella and/or varicella vaccination or disease or
             known exposure to any of these diseases within 30 days prior to the inclusion in the
             study.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, included
             the chronic administration (defined as more than 14 days) of immune-suppressants or
             other immune-modifying drugs within six months prior to the firs vaccine dose.

          -  History of any neurologic disorders or seizures.

          -  History of allergic diseases or reactions likely to be exacerbated by any component of
             the vaccines.

          -  Planned administration of a vaccine not foreseen by the study protocol from 30 days
             prior to each vaccination until 42-56 days after each vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Months</minimum_age>
    <maximum_age>22 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaston De Serres, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Quebec-Universite Laval</affiliation>
  </overall_official>
  <reference>
    <citation>Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine. 2009 Nov 5;27(47):6504-11. doi: 10.1016/j.vaccine.2009.07.076. Epub 2009 Aug 7. Review. Erratum in: Vaccine. 2012 Dec 14;30(52):7667. Vaccine. 2010 Dec 6;28(52):8352.</citation>
    <PMID>19665608</PMID>
  </reference>
  <reference>
    <citation>Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J. 2008 Aug;27(8):724-30. doi: 10.1097/INF.0b013e318170bb22. Erratum in: Pediatr Infect Dis J. 2013 Apr;32(4):e163.</citation>
    <PMID>18600190</PMID>
  </reference>
  <reference>
    <citation>Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, Descamps D, Willems P. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006 Jan;25(1):12-8.</citation>
    <PMID>16395096</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Gaston De Serres</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Measles vaccine</keyword>
  <keyword>Priorix</keyword>
  <keyword>Priorix-Tetra</keyword>
  <keyword>Age at vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

